Prognostic Analysis Of Epithelial Ovarian Cancer Patients And Evaluation Of Different Therapeutic Regimens

Objective:Analyze the relationship between the general clinical factors and prognosis of patients,and screen out the clinical factors that can predict the prognosis of epithelial ovarian cancer.Meanwhile,compare the effects of each treatment regimen on the treatment effect and prognosis of patients providing potential reference value for clinical medication.And provide ideas for further research on epithelial ovarian cancer.Methods:A total of 330 patients with ovarian epithelial cancer who were admitted to the Oncology Department of the First Hospital of Jilin University from January 2007 to January 2017 were enrolled.The general clinical data of the patients were recorded in detail.Survival curves were drawn by Kaplan-Meier method;correlations between factors were calculated using R language;data collation,screening and statistical analysis were performed using SPSS20.0 software;data visualization was performed using Cytoscape and Graphpad softwares.Results:1.The prognostic correlation of epithelial ovarian cancer shows that the five stages of disease staging,albumin level,CA125 level,ascites and cytoreductive status are at the core and closely related to the prognosis of patients.2.In the univariate analysis,the albumin level of patients had an important effect on PFS and OS(P=0.001);the OS of patients with CA125 value <500 U/ml was significantly prolonged(P=0.011),and there was no statistical difference in PFS.(P=0.108);OS was significantly shorter in patients with ascites(P=0.031),PFS was not significantly different(P =0.122);the later the stage,the greater the risk ofrecurrence(P =0.001),and the higher the risk of death(P =0.001);the worse the degree of differentiation,the higher the risk of tumor recurrence(P =0.012),the shorter the OS(P =0.029);the patients with lymph node metastasis were more likely to relapse(P =0.017),but had no significant effect on OS(P =0.097);PFS and OS in patients with satisfactory tumor reduction were significantly better than those without satisfactory tumor reduction(P =0.008,P =0.001).3.In multivariate analysis,patient stage and differentiation were independent risk factors for PFS(P =0.006,P =0.012);stage and dysfunction were the independent influencing factors of OS(P =0.042,P =0.009).4.In the FIGO stage III to IV patients,the PFS and OS were significantly prolonged in neoadjuvant therapy compared with direct surgery(P =0.0456).5.The efficacy of Paclitaxel combined with Platinum and Docetaxel combined with Platinum in the two first-line chemotherapy regimens was similar,and there was no significant difference in PFS between the two regimens(P=0.5837).6.Chemotherapy combined with antiangiogenic therapy showed significantly longer PFS compared with alb and liposomal Paclitaxel chemotherapy alone(P=0.0001).7.There was no significant difference in apatinib PFS between Bevacizumab and Apatinib.Conclusion:1.Albumin levels,stage of disease,degree of differentiation,lymph node metastasis,and cytoreductive status were associated with PFS in patients with EOC,and stage and degree of differentiation were independent risk factors for PFS in patients.2.CA125 levels,albumin levels,stage,degree of differentiation,ascites,and tumor-reducing satisfaction were associated with OS,and staging and cytoreduction were independent risk factors for OS.3.In patients with FIGO stage III-IV EOC,neoadjuvant chemotherapy caneffectively prolong PFS compared with direct surgical treatment.4.Chemotherapy combined with anti-angiogenesis therapy can significantly prolong the PFS of patients compared with the chemotherapy alone of albumin Paclitaxel and liposomal Paclitaxel.